Landscapes / Companies
Replimune, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
3
in active trials
Trials
8 active
10 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Gene therapy substances |
Approved in US | Jun 2028Phase 2 trial completes | |||
| How it works | A gene therapy | ||||
| Next date | Jun 2028 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H) and 10 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | 1 Dec 2027Phase 2 trial completes | |||
| Next date | 1 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Cancer, Hepatocellular Carcinoma and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Nov 2026soonPhase 1 trial completes | |||
| Next date | 30 Nov 2026 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumor | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021